Jazz Pharmaceuticals (JAZZ) Tops Q2 EPS by 53c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
Jazz Pharmaceuticals (JAZZ) PT Lowered to $174 at RBC Capital
August 1, 2024 6:26 AM EDTRBC Capital analyst Daniel Busb lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $174.00 (from $175.00) while maintaining a Outperform rating.
The analyst comments "JAZZ puts up solid 2Q commercial numbers (avoiding a guide cut as recently feared), while the removal of Vision... More
